We are aware of an issue causing the title of some ARTG entries to disappear. We are investigating as a priority and hope to have this resolved as soon as possible.
ELREXFIO (Pfizer Australia Pty Ltd)
Product name
ELREXFIO
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
243 (255 working days)
Active ingredients
elranatamab
Registration type
NCE/NBE
Indication
ELREXFIO has provisional approval in Australia and is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least 3 prior therapies, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody and have demonstrated disease progression on the last therapy.
The decision to approve this indication has been made on the basis of the overall response rate in a single arm study. Continued approval of this indication depends on verification and description of benefit in confirmatory trials.
Registration process
Provisional registration
Involves early access to vital and life-saving medicines through time-limited registration